Efficacy of the novel selective β3‐adrenoreceptor agonist vibegron for treatment‐resistant monosymptomatic nocturnal enuresis in children
- 19 May 2020
- journal article
- editorial
- Published by Wiley in International Journal of Urology
- Vol. 27 (8), 693-694
- https://doi.org/10.1111/iju.14264
Abstract
No abstract availableKeywords
This publication has 6 references indexed in Scilit:
- Efficacy of novel β3‐adrenoreceptor agonist vibegron on nocturia in patients with overactive bladder: A post‐hoc analysis of a randomized, double‐blind, placebo‐controlled phase 3 studyInternational Journal of Urology, 2018
- Constipation in nocturnal enuresis may interfere desmopressin management successJournal of Pediatric Urology, 2018
- Long-term safety and efficacy of the novel β3-adrenoreceptor agonist vibegron in Japanese patients with overactive bladder: A phase III prospective studyInternational Journal of Urology, 2018
- Vibegron, a Novel Potent and Selective β3-Adrenoreceptor Agonist, for the Treatment of Patients with Overactive Bladder: A Randomized, Double-blind, Placebo-controlled Phase 3 StudyEuropean Urology, 2018
- The Standardization of Terminology of Lower Urinary Tract Function in Children and Adolescents: Update Report from the Standardization Committee of the International Children's Continence SocietyJournal of Urology, 2014
- Evaluation of and Treatment for Monosymptomatic Enuresis: A Standardization Document From the International Children's Continence SocietyJournal of Urology, 2010